1
|
Mo Y, He X, Cui H, Cheng Y, Zhou M, Cui X, Zhang T. Gut microbiota: A new key of understanding for Panax notoginseng against multiple disorders and biotransformation. JOURNAL OF ETHNOPHARMACOLOGY 2025; 341:119306. [PMID: 39761836 DOI: 10.1016/j.jep.2024.119306] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/28/2024] [Revised: 12/26/2024] [Accepted: 12/28/2024] [Indexed: 01/14/2025]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Panax notoginseng (Burkill) F.H.Chen(P. notoginseng) has been widely used as an herbal medicine for reducing swelling, relieving pain, promoting blood circulation and stopping bleeding, with notable therapeutic effects on obesity, liver diseases, colitis, Alzheimer's disease, chronic kidney disease and other diseases. AIM OF THE STUDY This review highlighted the close link and bidirectional effects between P. notoginseng and gut microbiota, with the ultimate aim of providing new insights into the potential mechanisms of pharmacological effects of P. notoginseng in the treatment of different diseases and PNS transformation. MATERIALS AND METHODS By means of some reputable databases (PubMed, China National Knowledge Infrastructure (CNKI), Google Scholar, etc.), we screened the published articles related to P. notoginseng from 1998 to 2024, including original research, clinical trials and review on raw materials and chemical constituents of P. notoginseng. Then, we employed the keywords "gut microbiota", "intestinal microbiota", "gut biotransformation" and "intestinal" to exclude the articles that do not in line with our topic. Plant information was obtained from www.worldfloraonline.org using "Panax notoginseng (Burkill) F.H.Chen" as the keyword. RESULTS P. notoginseng elevated certain probiotics including Lactobacillus, Bifidobacterium and Akkermansia, while simultaneously reducing pathogenic bacteria such as Prevotellaceae, Enterococcus, Enterobacter and Helicobacter, to fight various diseases. Meanwhile, considering to the low oral bioavailability and degradable properties of Panax notoginseng saponin (PNS), gut microbiota converted it into protopanaxatriol(PPT) and protopanaxadiol(PPD) mainly through deglycosylation reactions to enhance the bioactivity. CONCLUSION Increasing evidences suggest that gut microbiota may play a vital role for P. notoginseng exerting on beneficial effects on the prevention and treatment of metabolic disorders, liver diseases, neurological diseases, chronic kidney diseases, vascular diseases, colitis, and other diseases, as well as for biotransformation of P. notoginseng.
Collapse
Affiliation(s)
- Yueting Mo
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
| | - Xiyuan He
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
| | - Hao Cui
- School of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Key Laboratory of Sustainable Utilization of Panax Notoginseng Resources of Yunnan Province, State Administration of Traditional Chinese Medicine, Kunming, 650500, China
| | - Yifan Cheng
- School of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Key Laboratory of Sustainable Utilization of Panax Notoginseng Resources of Yunnan Province, State Administration of Traditional Chinese Medicine, Kunming, 650500, China
| | - Mingmei Zhou
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
| | - Xiuming Cui
- School of Life Science and Technology, Kunming University of Science and Technology, Kunming, 650500, China; Key Laboratory of Sustainable Utilization of Panax Notoginseng Resources of Yunnan Province, State Administration of Traditional Chinese Medicine, Kunming, 650500, China.
| | - Ting Zhang
- Institute of Interdisciplinary Integrative Medicine Research, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
| |
Collapse
|
2
|
Rajakaruna S, Bandow B, Pérez-Burillo S, Navajas-Porras B, Rufián-Henares JÁ, Cool DR, Cho KJ, Paliy O. Human gut microbiota-fermented asparagus powder protects human epithelial cells from injury and inflammation. Food Funct 2025; 16:1060-1071. [PMID: 39821238 DOI: 10.1039/d4fo03504f] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2025]
Abstract
Dietary consumption of green asparagus has been associated with several health benefits. These beneficial properties are attributed to the presence of many bioactive compounds in asparagus, including saponins, phenolics, flavonoids, as well as dietary fiber mostly comprising fructans and inulins, which are prebiotics capable of supporting the growth of beneficial members of gut microbiota. In this study, we used the in vitro Human Gut Simulator system to assess the fermentation of oro-gastro-intestinally digested asparagus powder by the human gut microbiota. Microbial community composition differed between communities grown on the asparagus digest and on the Western diet derived medium. Asparagus supported beneficial Ruminococcus but also hydrogen sulfide producing members of Desulfovibrionaceae. Fermentation of asparagus released more antioxidants into the environment compared to the Western diet medium, and supernatant of asparagus-grown cultures protected cultured human epithelial cells against damage and inflammation. We thus showed that asparagus powder has potential to be used as a functional food, offering protection against intestinal damage and inflammation - effects mediated by the gut microbiota.
Collapse
Affiliation(s)
- Sumudu Rajakaruna
- Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
| | - Brant Bandow
- Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
| | - Sergio Pérez-Burillo
- Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
| | - Beatriz Navajas-Porras
- Department of Nutrition and Food Sciences, Instituto de Nutrición y Tecnología de los Alimentos, Centro de Investigación Biomédica, University of Granada, Granada, Spain.
| | - José Ángel Rufián-Henares
- Department of Nutrition and Food Sciences, Instituto de Nutrición y Tecnología de los Alimentos, Centro de Investigación Biomédica, University of Granada, Granada, Spain.
- Instituto de Investigación Biosanitaria ibs.GRANADA, University de Granada, Granada, Spain.
| | - David R Cool
- Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
| | - Kwang-Jin Cho
- Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
| | - Oleg Paliy
- Department of Biochemistry and Molecular Biology, Boonshoft School of Medicine, Wright State University, Dayton, Ohio, USA.
| |
Collapse
|
3
|
Liu J, Shao L, Zhou J, Li SF, Huang JM, Peng JB, Zhang W, Wan JB, Huang WH. Metabolic characteristics of saponins from Panax notoginseng leaves biotransformed by gut microbiota in rats. ANALYTICAL METHODS : ADVANCING METHODS AND APPLICATIONS 2025; 17:972-989. [PMID: 39810648 DOI: 10.1039/d4ay01941e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/16/2025]
Abstract
Saponins are responsible for the clinical effects of Panax notoginseng leaves, which are traditionally produced as the single herb resource of 'Qiye Shenan Pian' in Chinese patent medicine. In this study, the metabolic characteristics of PNLSs were explored in rat feces. PNLSs as well as their metabolites were analyzed by ultra-performance liquid chromatography tandem/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS/MS). Subsequently, seventy-five metabolites were tentatively identified in the control group mainly due to the deglycosylation and dehydration biopathways, but only twenty low yields were determined in the pseudo-germ-free (GF) group. Ginsenoside compound K was the predominant metabolite in the control group. The data presented that gut microbiota played a pivotal role in the metabolic kinetics of PNLSs.
Collapse
Affiliation(s)
- Jing Liu
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| | - Li Shao
- Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan 410128, China.
| | - Jie Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| | - Shuang-Feng Li
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| | - Jia-Meng Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| | - Jing-Bo Peng
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| | - Wei Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| | - Jian-Bo Wan
- State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau
| | - Wei-Hua Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China.
| |
Collapse
|
4
|
Feng MG, Xiang LH, Li Y, Bai RR, Feng ZM, Zhao ZG, Dou ZY, Zhao WH, Guo H, Lv Y, Zhang J, Liu GX, Cai SQ, Xu F. Existing Forms of Notoginsenoside R 1 in Rats and Their Potential Bioactivities. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2024; 72:27248-27264. [PMID: 39611556 DOI: 10.1021/acs.jafc.4c09227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/30/2024]
Abstract
Notoginsenoside R1 (NG-R1) is a primary active constituent in Panax notoginseng, a medicinal and edible plant. It is a saponin with protopanaxatriol (PPT) as its aglycone. UHPLC-ESI-Q-TOF-MS/MS was used to clarify the existing forms of NG-R1 and their distributions in rats. The nomenclature of the ESI MS fragmentation pathway and ions of PPT was proposed for the first time. Totally, 105 metabolites with 89 new metabolites were identified. In terms of their LC-MS data, 7 were accurately identified by comparison with reference compounds, and 41 were clearly identified. Polyhydroxylation, pentosylation, acetylation, glucuronidation, and amino acid conjugation are new metabolic reactions of NG-R1. In total, 69, 48, 47, 43, 24, 15, and 7 metabolites were detected in the large intestine, stomach, small intestine, liver, lungs, kidneys, and heart, respectively. Then, 48 metabolites were predicted to be effective by PharmMapper, and their mechanisms of action on three diseases were predicted by network pharmacology. Finally, the antitumor effects on cell proliferation and the anti-inflammatory effects of the eight compounds were verified by cellular experiments. These results help further elucidate the in vivo existing forms of dammarane-type triterpenoids and form the basis for discovering their effective forms in the future.
Collapse
Affiliation(s)
- Meng-Ge Feng
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
- Medical College of Tibet University, Lasa 850002, China
| | - Lin-Han Xiang
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Yang Li
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Rong-Rong Bai
- Medical College of Tibet University, Lasa 850002, China
| | - Zi-Meng Feng
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Zhi-Gao Zhao
- College of Life Science and Engineering, Southwest Jiaotong University, Chengdu 610031, China
| | - Zhi-Yang Dou
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Wen-Hui Zhao
- Medical College of Tibet University, Lasa 850002, China
| | - Hui Guo
- Medical College of Tibet University, Lasa 850002, China
| | - Yang Lv
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Jing Zhang
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 310053, China
| | - Guang-Xue Liu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
| | - Shao-Qing Cai
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
- Medical College of Tibet University, Lasa 850002, China
| | - Feng Xu
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
- Medical College of Tibet University, Lasa 850002, China
| |
Collapse
|
5
|
Wang H, Zhou L, Zheng Q, Song Y, Huang W, Yang L, Xiong Y, Cai Z, Chen Y, Yuan J. Kai-xin-san improves cognitive impairment in D-gal and Aβ 25-35 induced ad rats by regulating gut microbiota and reducing neuronal damage. JOURNAL OF ETHNOPHARMACOLOGY 2024; 329:118161. [PMID: 38599474 DOI: 10.1016/j.jep.2024.118161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 04/03/2024] [Accepted: 04/05/2024] [Indexed: 04/12/2024]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Kai-Xin-San (KXS) is a classic herbal formula for the treatment and prevention of AD (Alzheimer's disease) with definite curative effect, but its mechanism, which involves multiple components, pathways, and targets, is not yet fully understood. AIM OF THE STUDY To verify the effect of KXS on gut microbiota and explore its anti-AD mechanism related with gut microbiota. MATERIALS AND METHODS AD rat model was established and evaluated by intraperitoneal injection of D-gal and bilateral hippocampal CA1 injections of Aβ25-35. The pharmacodynamics of KXS in vivo includes general behavior, Morris water maze test, ELISA, Nissl & HE staining and immunofluorescence. Systematic analysis of gut microbiota was conducted using 16S rRNA gene sequencing technology. The potential role of gut microbiota in the anti-AD effect of KXS was validated with fecal microbiota transplantation (FMT) experiments. RESULTS KXS could significantly improve cognitive impairment, reduce neuronal damage and attenuate neuroinflammation and colonic inflammation in vivo in AD model rats. Nine differential intestinal bacteria associated with AD were screened, in which four bacteria (Lactobacillus murinus, Ligilactobacillus, Alloprevotella, Prevotellaceae_NK3B31_group) were very significant. CONCLUSION KXS can maintain the ecological balance of intestinal microbiota and exert its anti-AD effect by regulating the composition and proportion of gut microbiota in AD rats through the microbiota-gut-brain axis.
Collapse
Affiliation(s)
- Huijuan Wang
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Lifen Zhou
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Qin Zheng
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Yonggui Song
- Laboratory Animal Science and Technology Development Center, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Weihua Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, and National Clinical Research Center for Geriatric Disorders, Central South University, Changsha, 410008, China
| | - Lin Yang
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Yongchang Xiong
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Zhinan Cai
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Ying Chen
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China
| | - Jinbin Yuan
- Key Lab of Modern Preparations of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, 330004, China.
| |
Collapse
|
6
|
Ma Y, Zhao Y, Luo M, Jiang Q, Liu S, Jia Q, Bai Z, Wu F, Xie J. Advancements and challenges in pharmacokinetic and pharmacodynamic research on the traditional Chinese medicine saponins: a comprehensive review. Front Pharmacol 2024; 15:1393409. [PMID: 38774213 PMCID: PMC11106373 DOI: 10.3389/fphar.2024.1393409] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 04/12/2024] [Indexed: 05/24/2024] Open
Abstract
Recent research on traditional Chinese medicine (TCM) saponin pharmacokinetics has revealed transformative breakthroughs and challenges. The multicomponent nature of TCM makes it difficult to select representative indicators for pharmacokinetic studies. The clinical application of saponins is limited by their low bioavailability and short half-life, resulting in fluctuating plasma concentrations. Future directions should focus on novel saponin compounds utilizing colon-specific delivery and osmotic pump systems to enhance oral bioavailability. Optimizing drug combinations, such as ginsenosides with aspirin, shows therapeutic potential. Rigorous clinical validation is essential for practical applications. This review emphasizes a transformative era in saponin research, highlighting the need for clinical validation. TCM saponin pharmacokinetics, guided by traditional principles, are in development, utilizing multidisciplinary approaches for a comprehensive understanding. This research provides a theoretical basis for new clinical drugs and supports rational clinical medication.
Collapse
Affiliation(s)
- Yuhan Ma
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Yongxia Zhao
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Mingxia Luo
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Qin Jiang
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Sha Liu
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Qi Jia
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Zhixun Bai
- Organ Transplant Center, Affiliated Hospital of Zunyi Medical University, Zunyi, China
| | - Faming Wu
- School of Pharmacy, Zunyi Medical University, Zunyi, China
| | - Jian Xie
- School of Pharmacy, Zunyi Medical University, Zunyi, China
- School of Preclinical Medicine, Zunyi Medical University, Zunyi, China
| |
Collapse
|
7
|
Wang L, Shao L, Huang STZ, Liu Z, Zhang W, Hu K, Huang WH. Metabolic characteristics of ginsenosides from Panax ginseng in rat feces mediated by gut microbiota. J Pharm Biomed Anal 2024; 237:115786. [PMID: 37837893 DOI: 10.1016/j.jpba.2023.115786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 09/21/2023] [Accepted: 10/09/2023] [Indexed: 10/16/2023]
Abstract
Ginsenosides in Panax ginseng are regarded to be functional ingredients for diverse pharmacological effects and orally administrated with very low absorption in the gastrointestinal tract to be metabolized by gut microbiota. However, in vivo metabolic characteristics of ginsenosides mediated by gut microbiota are not well-known. This study aimed to explore the metabolic profiles of ginsenosides in rat feces mediated by gut microbiota. Ginsenosides and metabolites were identified and relatively quantified by ultra-performance liquid chromatography tandem/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS/MS). As a result, eighty-four metabolites were identified in the normal control rat feces, while only thirty intermediates were found with very low yields in the pseudo-germ-free (GF) group. Similarly, the main bioconversion pathways of ginsenosides in vivo were the same deglycosylation reaction mediated by gut microbiota in vitro. The findings demonstrated significant differences in metabolic profiles between the normal control and pseudo-GF rats, which implied gut microbiota played an important role in the metabolism of ginsenosides.
Collapse
Affiliation(s)
- Lin Wang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
| | - Li Shao
- Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan 410128, China
| | - Su-Tian-Zi Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
| | - Zhi Liu
- College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China
| | - Wei Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China
| | - Kai Hu
- Department of Neurology, Xiangya Hospital, Central South University, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
| | - Wei-Hua Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
| |
Collapse
|
8
|
Montagnani M, Potenza MA, Corsalini M, Barile G, Charitos IA, De Giacomo A, Jirillo E, Colella M, Santacroce L. Current View on How Human Gut Microbiota Mediate Metabolic and Pharmacological Activity of Panax ginseng. A Scoping Review. Endocr Metab Immune Disord Drug Targets 2024; 24:1756-1773. [PMID: 38504564 DOI: 10.2174/0118715303270923240307120117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2023] [Revised: 10/03/2023] [Accepted: 01/05/2024] [Indexed: 03/21/2024]
Abstract
Panax ginseng is one of the most important remedies in ancient Eastern medicine. In the modern Western world, its reputation started to grow towards the end of the XIX century, but the rather approximate understanding of action mechanisms did not provide sufficient information for an appropriate use. Nowadays, Panax ginseng is frequently used in some pathological conditions, but the comprehension of its potential beneficial effects is still incomplete. The purpose of this study is to highlight the most recent knowledge on mechanisms and effects of ginseng active ingredients on the intestinal microbiota. The human microbiota takes part in the immune and metabolic balance and serves as the most important regulator for the control of local pathogens. This delicate role requires a complex interaction and reflects the interconnection with the brainand the liver-axes. Thus, by exerting their beneficial effects through the intestinal microbiota, the active ingredients of Panax ginseng (glycosides and their metabolites) might help to ameliorate both specific intestinal conditions as well as the whole organism's homeostasis.
Collapse
Affiliation(s)
- Monica Montagnani
- Department of Precision Medicine and Ionian Area, Section of Pharmacology, School of Medicine, University of Bari "Aldo Moro," Policlinico University Hospital of Bari, Bari, Italy
| | - Maria Assunta Potenza
- Department of Precision Medicine and Ionian Area, Section of Pharmacology, School of Medicine, University of Bari "Aldo Moro," Policlinico University Hospital of Bari, Bari, Italy
| | - Massimo Corsalini
- Interdisciplinary Department of Medicine, School of Medicine, University of Bari "Aldo Moro", Bari, Italy
| | - Giuseppe Barile
- Interdisciplinary Department of Medicine, School of Medicine, University of Bari "Aldo Moro", Bari, Italy
| | - Ioannis Alexandros Charitos
- Istituti Clinici Scientifici Maugeri IRCCS, Pneumology and Respiratory Rehabilitation Unit, "Istitute" of Bari, Bari, Italy
| | - Andrea De Giacomo
- Department of Neurological and Psychiatric Sciences, University of Bari Aldo Moro, Bari, Italy
| | - Emilio Jirillo
- Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University of Bari "Aldo Moro", Bari, Italy
| | - Marica Colella
- Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University of Bari "Aldo Moro", Bari, Italy
- Doctoral School, eCampus University, Novedrate, Italy
| | - Luigi Santacroce
- Interdisciplinary Department of Medicine, Section of Microbiology and Virology, School of Medicine, University of Bari "Aldo Moro", Bari, Italy
| |
Collapse
|
9
|
Zhao L, Sui M, Zhang T, Zhang K. The interaction between ginseng and gut microbiota. Front Nutr 2023; 10:1301468. [PMID: 38045813 PMCID: PMC10690783 DOI: 10.3389/fnut.2023.1301468] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2023] [Accepted: 11/02/2023] [Indexed: 12/05/2023] Open
Abstract
The importance of the gut microbiota to human health is attracting increasing attention. It is also involved in ginseng metabolism, mediating the bioactive metabolites of ginsenosides. In response, ginseng, known as the king of herbs, can regulate intestinal flora, including promoting probiotics and restricting the growth of harmful bacteria. Specifically, the interactions between ginseng or ginsenosides and gastrointestinal microbiota are complex. In this review, we summarized the effects of ginseng and ginsenosides on the composition of gut microbiota and discussed the gut microbiota-mediated biotransformation of ginsenosides. In particular, their therapeutic potential and clinical application in related diseases were also summarized.
Collapse
Affiliation(s)
| | | | | | - Kai Zhang
- Department of General Surgery, The Second Hospital of Jilin University, Changchun, China
| |
Collapse
|
10
|
Chen J, Lu P, Liu J, Yang L, Li Y, Chen Y, Wang Y, Wan J, Zhao Y. 20(S)- Protopanaxadiol saponins isolated from Panax notoginseng target the binding of HMGB1 to TLR4 against inflammation in experimental ulcerative colitis. Phytother Res 2023; 37:4690-4705. [PMID: 37424151 DOI: 10.1002/ptr.7938] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 06/15/2023] [Accepted: 06/24/2023] [Indexed: 07/11/2023]
Abstract
Ulcerative colitis (UC) has emerged as a global healthcare issue due to high prevalence and unsatisfying therapeutic measures. 20(S)- Protopanaxadiol saponins (PDS) from Panax notoginseng with anti-inflammatory properties is a potential anti-colitis agent. Herein, we explored the effects and mechanisms of PDS administration on experimental murine UC. Dextran sulfate sodium-induced murine UC model was employed to investigate anti-colitis effects of PDS, and associated mechanisms were further verified in HMGB1-exposed THP-1 macrophages. Results indicated that PDS administration exerted ameliorative effects against experimental UC. Moreover, PDS administration remarkably downregulated mRNA expressions and productions of related pro-inflammatory mediators, and reversed elevated expressions of proteins related to NLRP3 inflammasome after colitis induction. Furthermore, administration with PDS also suppressed the expression and translocation of HMGB1, interrupting the downstream TLR4/NF-κB pathway. In vitro, ginsenoside CK and 20(S)-protopanaxadiol, the metabolites of PDS, exhibited greater potential in anti-inflammation, and intervened with the TLR4-binding domain of HMGB1 predictably. Expectedly, ginsenoside CK and 20(S)-protopanaxadiol administrations inhibited the activation of TLR4/NF-κB/NLRP3 inflammasome pathway in HMGB1-exposed THP-1 macrophages. Summarily, PDS administration attenuated inflammatory injury in experimental colitis by blocking the binding of HMGB1 to TLR4, majorly attributed to the antagonistic efficacies of ginsenoside CK and 20(S)-protopanaxadiol.
Collapse
Affiliation(s)
- Jinfen Chen
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Pengde Lu
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Jiayue Liu
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Li Yang
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Yiyang Li
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Yanling Chen
- Department of Pathophysiology, Zhuhai Campus of Zunyi Medical University, Zhuhai, Guangdong, China
| | - Yitao Wang
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Jianbo Wan
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
| | - Yonghua Zhao
- Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in Chinese Medicine, University of Macau, Taipa, Macao SAR, China
- Guangdong-Hong Kong-Macau Joint Lab on Chinese Medicine and Immune Disease Research, University of Macau, Taipa, Macao SAR, China
| |
Collapse
|
11
|
Xu Y, Zhu M, Feng Y, Xu H. Panax notoginseng-microbiota interactions: From plant cultivation to medicinal application. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2023; 119:154978. [PMID: 37549538 DOI: 10.1016/j.phymed.2023.154978] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Revised: 06/25/2023] [Accepted: 07/15/2023] [Indexed: 08/09/2023]
Abstract
BACKGROUND Microbiomes and their host plants are closely linked with each other; for example, the microbiome affects plant growth, fitness, nutrient uptake, stress tolerance and pathogen resistance, whereas the host plant supports the photosynthetically carbon-rich nutrition of the microbiome. The importance of the microbiome in plant‒soil ecosystems is unquestioned and has expanded to influence the medicinal application of some herbal plants via the gut microbiota. PURPOSE Herbal plant-microbiome interactions may provide novel knowledge to enhance the robustness of herbal plant crop performance and medicinal applications, which requires a systematic review and preceding discussion. STUDY DESIGN AND METHODS The interactions between Panax notoginseng and microorganisms (from soil to host) were reviewed from the literature. The terms "Panax notoginseng" and "microbiota" were used in combination with the keywords "microbiota/microbes", "bacteria/bacterium" or "fungi/fungus" or "endophyte", as well as our targeted bioactive phytochemicals, including saponins and ginsenosides. RESULT Our study focuses on the famous medicinal herb Panax notoginseng F. H. Chen and proposes that the microbiota is a crucial participant not only in the cultivation of this herbal plant but also in its medicinal application. We also summarize and discuss how these plant‒microbe co-associations shape the assembly of plant-related microbiomes and produce bioactive phytochemicals, as well as influence beneficial herbal traits, such as herbal plant health and pharmacology. In addition, we also highlight future directions. CONCLUSION The rhizosphere and endophytic microbiome of Panax notoginseng are indirectly or directly involved in plant health, biomass production, and the synthesis/biotransformation of plant secondary metabolites. Harnessing the microbiome to improve the quality of traditional Chinese medicine and improve the value of medicinal plants for human health is highly promising.
Collapse
Affiliation(s)
- Yu Xu
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Mengjie Zhu
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
| | - Yibin Feng
- School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong.
| | - Hongxi Xu
- Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, PR China.
| |
Collapse
|
12
|
Li S, Hao L, Hu X. Natural products target glycolysis in liver disease. Front Pharmacol 2023; 14:1242955. [PMID: 37663261 PMCID: PMC10469892 DOI: 10.3389/fphar.2023.1242955] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2023] [Accepted: 08/10/2023] [Indexed: 09/05/2023] Open
Abstract
Mitochondrial dysfunction plays an important role in the occurrence and development of different liver diseases. Oxidative phosphorylation (OXPHOS) dysfunction and production of reactive oxygen species are closely related to mitochondrial dysfunction, forcing glycolysis to become the main source of energy metabolism of liver cells. Moreover, glycolysis is also enhanced to varying degrees in different liver diseases, especially in liver cancer. Therefore, targeting the glycolytic signaling pathway provides a new strategy for the treatment of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis associated with liver cancer. Natural products regulate many steps of glycolysis, and targeting glycolysis with natural products is a promising cancer treatment. In this review, we have mainly illustrated the relationship between glycolysis and liver disease, natural products can work by targeting key enzymes in glycolysis and their associated proteins, so understanding how natural products regulate glycolysis can help clarify the therapeutic mechanisms these drugs use to inhibit liver disease.
Collapse
Affiliation(s)
- Shenghao Li
- Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Liyuan Hao
- Chengdu University of Traditional Chinese Medicine, Chengdu, China
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Xiaoyu Hu
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China
| |
Collapse
|
13
|
Liu F, Nong X, Qu W, Li X. Pharmacokinetics and tissue distribution of 12 major active components in normal and chronic gastritis rats after oral administration of Weikangling capsules. JOURNAL OF ETHNOPHARMACOLOGY 2023:116722. [PMID: 37271330 DOI: 10.1016/j.jep.2023.116722] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2023] [Revised: 05/28/2023] [Accepted: 05/31/2023] [Indexed: 06/06/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Weikangling Capsules (WKLCs) have been used in the clinic for the treatment of gastrointestinal disorders for more than 30 years. However, the pharmacokinetic characteristics and tissue distribution of its major bioactive components in rats under different physiological and pathological conditions are unclear. AIM OF THE STUDY In this study, we aimed to clarify the differences in pharmacokinetic parameters and tissue distribution of the major active components in WKLCs under physiological and pathological states. MATERIALS AND METHOD Normal and ethanol-induced chronic gastritis rats received 2.16 g/kg WKLCs by gavage, and urine, feces, plasma, and tissue (heart, liver, spleen, lung, kidney, stomach, and small intestine) samples were obtained. The active components in urine, feces and plasma were detected by ultra-high-performance liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry (UHPLC-Q-TOF-MS/MS). A rapid and sensitive analytical method, ultra-high-performance liquid chromatography coupled with triple-quadrupole linear ion-trap tandem mass spectrometry (UHPLC-QTRAP-MS/MS), was established and validated to clarify and compare the pharmacokinetics and tissue distribution of the major active components in normal and chronic gastritis rats. RESULTS A total of 36 chemical components in the feces, urine, and plasma of chronic gastritis rats were identified by UHPLC-Q-TOF-MS/MS. Among them, 20 were the prototype components of WKLCs, and 16 were metabolites. The pharmacokinetic characteristics and tissue distribution of 12 prototype components were successfully analyzed by UHPLC-QTRAP-MS/MS. The pharmacokinetic results showed that the Cmax, AUC0-t, and AUC0-∞ of paeoniflorin, glycyrrhizic acid, and glycyrrhetinic acid were distinctly higher than those of the other components in normal and chronic gastritis rats. Compared to normal rats, the Cmax, AUC0-t, and AUC0-∞ of albiflorin, liquiritin apioside, liquiritin, isoliquiritin, ononin, isoliquiritigenin, dactylorhin A, and glycyrrhizic acid were significantly increased in chronic gastritis rats (P < 0.05), while the Cmax, AUC0-t and AUC0-∞ of militarine and liquiritigenin had significantly lower decreases in chronic gastritis rats (P < 0.05). The results of the tissue distribution showed that the 12 components were widely distributed in the heart, liver, spleen, lung, kidney, stomach, and small intestine of rats, of which the liver, kidney, stomach, and small intestine were the main accumulative organs. Compared with normal rats, the concentrations of 12 components in the liver, kidney, stomach, and small intestine of chronic gastritis rats were widely higher than those of normal rats at the same time points. CONCLUSION The pharmacokinetic characteristics and tissue distribution of 12 active components of WKLCs were comprehensively characterized and elucidated in normal and chronic gastritis rats. These findings laid a solid foundation for revealing the pharmacodynamic material basis of WKLCs in treating gastrointestinal disorders.
Collapse
Affiliation(s)
- Feng Liu
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Xiaojing Nong
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China
| | - Wenhua Qu
- Heilongjiang Sunflower Pharmaceutical Co. Ltd., Heilongjiang, 150070, China
| | - Xiaobo Li
- School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
| |
Collapse
|
14
|
Yang H, Zhang Y, Zhou R, Wu T, Zhu P, Liu Y, Zhou J, Xiong Y, Xiong Y, Zhou H, Zhang W, Shu Y, Li X, Li Q. Antibiotics-Induced Depletion of Rat Microbiota Induces Changes in the Expression of Host Drug-Processing Genes and Pharmacokinetic Behaviors of CYPs Probe Drugs. Drug Metab Dispos 2023; 51:509-520. [PMID: 36623881 DOI: 10.1124/dmd.122.001173] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2022] [Revised: 12/10/2022] [Accepted: 12/16/2022] [Indexed: 01/11/2023] Open
Abstract
The metabolism of exogenous substances is affected by the gut microbiota, and the relationship between them has become a hot topic. However, the mechanisms by which the microbiota regulates drug metabolism have not been clearly defined. This study characterizes the expression profiles of host drug-processing genes (DPGs) in antibiotics-treated rats by using an unbias quantitative RNA-sequencing method and investigates the effects of antibiotics-induced depletion of rat microbiota on the pharmacokinetic behaviors of cytochrome P450s (CYPs) probe drugs, and bile acids metabolism by ultra-performance liquid chromatography-tandem mass spectrometry. Our results show that antibiotics treatments altered the mRNA expressions of 112 DPGs in the liver and jejunum of rats. The mRNA levels of CYP2A1, CYP2C11, CYP2C13, CYP2D, CYP2E1, and CYP3A of CYP family members were significantly downregulated in antibiotics-treated rats. Furthermore, antibiotics treatments also resulted in a significant decrease in the protein expressions and enzyme activities of CYP3A1 and CYP2E1 in rat liver. Pharmacokinetic results showed that, except for tolbutamide, antibiotics treatments significantly altered the pharmacokinetic behaviors of phenacetin, omeprazole, metoprolol, chlorzoxazone, and midazolam. In conclusion, the presence of stable, complex, and diverse gut microbiota plays a significant role in regulating the expression of host DPGs, which could contribute to some individual differences in pharmacokinetics. SIGNIFICANCE STATEMENT: This study investigated how the depletion of rat microbiota by antibiotics treatments influences the expression profiles of host DPGs and the pharmacokinetic behaviors of CYPs probe drugs. Combined with previous studies in germ-free mice, this study will improve the understanding of the role of gut microbiota in drug metabolism and contribute to the understanding of individual differences in the pharmacokinetics of some drugs.
Collapse
Affiliation(s)
- Haijun Yang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Yanjuan Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Rong Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Tianyuan Wu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Peng Zhu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Yujie Liu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Jian Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Yalan Xiong
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Yanling Xiong
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Honghao Zhou
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Wei Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Yan Shu
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Xiong Li
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| | - Qing Li
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., X.L., Q.L.); National Clinical Research Center for Geriatric Disorders, Changsha, China (H.Y., Y.Z., R.Z., T.W., P.Z., Y.L., J.Z., Yalan X., Yanling X., H.Z., W.Z., Q.L.); Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland at Baltimore, Maryland (Y.S.); and Key Specialty of Clinical Pharmacy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China (X.L.)
| |
Collapse
|
15
|
Liu Q, Pei Y, Wan H, Wang M, Liu L, Li W, Jin J, Liu X. Chemical profiling and identification of Radix Cudramiae and their metabolites in rats using an ultra-high-performance liquid chromatography method coupled with time-of-flight tandem mass spectrometry. J Sep Sci 2023; 46:e2200767. [PMID: 36538732 DOI: 10.1002/jssc.202200767] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2022] [Revised: 11/28/2022] [Accepted: 12/06/2022] [Indexed: 12/24/2022]
Abstract
Radix Cudramiae, known as "Chuan-Po-Shi" in China, is a herbal medicine widely used in the southwest of the country, especially applied by the Miao and Zhuang nationalities for the treatment of liver diseases, such as acute liver injury and liver fibrosis. As a kind of ethnomedicine, the report on its chemical analysis was still blank, which restricted its clinical application. Therefore, this paper aimed to illustrate the chemical characteristics of Radix Cudramiae. A rapid analytical strategy based on ultra-high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry was developed to profile the natural small-molecular compounds in Radix Cudramiae, as well as the related prototypes and their metabolites in rats after drug administration. As a result, a total of 74 compounds were detected in the aqueous exact of Radix Cudramiae. In vivo, 45 chemicals including 16 prototypes and 29 metabolites in rat serum, along with 35 chemicals including 17 prototypes and 18 metabolites in rat liver, were screened out and identified. For the first time, the chemical constituents of Radix Cudramiae and their metabolic characteristics were discovered. It was hoped that this work would be beneficial for the safe and effective application of Radix Cudramiae in a clinic.
Collapse
Affiliation(s)
- Qing Liu
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| | - Yuqiong Pei
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| | - Haoting Wan
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| | - Mengqing Wang
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| | - Luyao Liu
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| | - Weidong Li
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| | - Junjie Jin
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Department of TCM Quality, Nanjing Haichang Chinese Medicine Group Corporation, Nanjing, P. R. China
| | - Xiao Liu
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, P. R. China.,Engineering Center of State Ministry of Education for Standardization of Chinese Medicine Processing, Nanjing University of Chinese Medicine, Nanjing, P. R. China
| |
Collapse
|
16
|
Zhang NN, Jiang ZM, Li SZ, Yang X, Liu EH. Evolving interplay between natural products and gut microbiota. Eur J Pharmacol 2023; 949:175557. [PMID: 36716810 DOI: 10.1016/j.ejphar.2023.175557] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2022] [Revised: 01/23/2023] [Accepted: 01/26/2023] [Indexed: 01/29/2023]
Abstract
Growing evidence suggests gut microbiota status affects human health, and microbiota imbalance will induce multiple disorders. Natural products are gaining increasing attention for their therapeutical effects and less side effects. The emerging studies support that the activities of many natural products are dependent on gut microbiota, meanwhile gut microbiota is modulated by natural products. In this review, we summarized the interplay between the gut microbiota and host disease, and the emerging molecular mechanisms of the interaction between natural products and gut microbiota. Focusing on gut microbiota metabolite of various natural products, and the effects of natural products on gut microbiota, we summarized the biotransformation pathways of natural products, and discussed the effect of natural products on the composition modulation of gut microbiota, protection of gut mucosal barrier and modulation of the gut microbiota metabolites. Dissecting the interplay between gut microbiota and natural products will help elucidate the therapeutic mechanisms of natural products.
Collapse
Affiliation(s)
- Ning-Ning Zhang
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | - Zheng-Meng Jiang
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | - Shang-Zhen Li
- Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine, Nanjing, China
| | - Xing Yang
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China
| | - E-Hu Liu
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China.
| |
Collapse
|
17
|
Fu X, Chen K, Li Z, Fan H, Xu B, Liu M, Guo L, Xie Z, Liu K, Zhang S, Kou L. Pharmacokinetics and Oral Bioavailability of Panax Notoginseng Saponins Administered to Rats Using a Validated UPLC-MS/MS Method. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 2023; 71:469-479. [PMID: 36576094 DOI: 10.1021/acs.jafc.2c06312] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/17/2023]
Abstract
Panax notoginseng saponins (PNS) are the most important bioactive components of P. Notoginseng. In this paper, an evaluation of the pharmacokinetics and oral absolute bioavailability of PNS was carried out following intravenous and oral administration of PNS to Sprague-Dawley rats. The plasma concentration of 28 PNS was determined using a validated UPLC-MS/MS system. The results demonstrated that Rb1(32.8%), Rg1(41.4%), R1(9.4%), Re(4.5%), and Rd(3.5%) are the five main ingredients of PNS for administration. After oral administration, it was found that the area under the curve (AUC0-72 h) for these five major saponins was significantly different. AUC0-72 h of Rb1 and Rd accounted for about 60% of all PNS exposure, while AUC0-72 h of Rg1 and R1 only accounted for 0.7%, and Re was undetectable in plasma. Also, PPD, PPT, and CK were detected as the major PNS metabolites in vivo. Furthermore, it was shown that the total oral bioavailability of PNS was only 1.2%.
Collapse
Affiliation(s)
- Xinzhen Fu
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| | - Kun Chen
- School of Pharmacy, Yantai University, Yantai264003, China
| | - Zhi Li
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| | - Huaying Fan
- School of Pharmacy, Yantai University, Yantai264003, China
| | - Bo Xu
- School of Pharmacy, Yantai University, Yantai264003, China
| | - Ming Liu
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| | - Lin Guo
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| | - Zeping Xie
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| | - Ke Liu
- Shandong Boyuan Biomedical Co., Ltd., Yantai264003, China
| | - Shumin Zhang
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| | - Lijuan Kou
- School of Pharmacy, Binzhou Medical University, Yantai264003, China
| |
Collapse
|
18
|
Wang L, Shao L, Chen MY, Wang L, Zhang W, Tan FB, Huang WH. Effect of ginsenoside compound K on alleviating colitis via modulating gut microbiota. Chin Med 2022; 17:146. [PMID: 36578000 PMCID: PMC9795722 DOI: 10.1186/s13020-022-00701-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 12/14/2022] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Ginsenoside compound K (GC-K) potentially alleviates ulcerative colitis involved in gut microbiota, which is significantly associated with the occurrence and development of colitis. However, the effect and mechanism of GC-K on anti-colitis in relation to gut microbiota are not clear. This study focused on the prevention and mechanism of GC-K on Dextran sulfate sodium (DSS)-induced colitis of mice pertinent to gut microbiota. METHODS DSS was used to establish a chronic colitis mouse model. Body weight analysis, colon length measurement, HE staining, and inflammatory factors levels were processed in animal experiments. Flow cytometry was employed to analyze Th17/Treg cells in the mouse spleen and blood. 16S rRNA sequencing was utilized to analyze gut microbiota. Fecal microbiota transplantation (FMT) experiment was employed to verify the anti-colitis efficacy of GC-K by reshaping gut microbiota. RESULTS GC-K significantly relieved colitis-related symptoms due to decreased disease activity index (DAI) scores, spleen weight, and increased colon length. Additionally, the tight junction proteins were increased, and the pro-inflammatory cytokines, such as TNF-α, IL-6, IL-1β and IL-17, were decreased after GC-K treatment. Furthermore, Bacteroides spp. significantly increased after modeling. Moreover, FMT experiments confirmed that GC-K-driven gut microbiota greatly relieved DSS-induced colitis. CONCLUSION GC-K alleviated colitis via the modulation of gut microbiota.
Collapse
Affiliation(s)
- Li Wang
- grid.452223.00000 0004 1757 7615Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008 China ,grid.216417.70000 0001 0379 7164Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078 China ,grid.452223.00000 0004 1757 7615National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 China
| | - Li Shao
- grid.488482.a0000 0004 1765 5169Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410128 China
| | - Man-Yun Chen
- grid.452223.00000 0004 1757 7615Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008 China ,grid.216417.70000 0001 0379 7164Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078 China ,grid.452223.00000 0004 1757 7615National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 China
| | - Lin Wang
- grid.452223.00000 0004 1757 7615Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008 China ,grid.216417.70000 0001 0379 7164Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078 China ,grid.452223.00000 0004 1757 7615National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 China
| | - Wei Zhang
- grid.452223.00000 0004 1757 7615Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008 China ,grid.216417.70000 0001 0379 7164Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078 China ,grid.452223.00000 0004 1757 7615National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 China
| | - Feng-Bo Tan
- grid.452223.00000 0004 1757 7615Department of General Surgery, Xiangya Hospital, Central South University, Changsha, 410008 China
| | - Wei-Hua Huang
- grid.452223.00000 0004 1757 7615Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008 China ,grid.216417.70000 0001 0379 7164Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078 China ,grid.452223.00000 0004 1757 7615National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, 410008 China
| |
Collapse
|
19
|
A Comparative Study of Serum Pharmacochemistry of Kai-Xin-San in Normal and AD Rats Using UPLC-LTQ-Orbitrap-MS. Pharmaceuticals (Basel) 2022; 16:ph16010030. [PMID: 36678527 PMCID: PMC9866203 DOI: 10.3390/ph16010030] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Revised: 12/15/2022] [Accepted: 12/20/2022] [Indexed: 12/28/2022] Open
Abstract
Kai-Xin-San (KXS) is a classic formula for the treatment of Alzheimer's disease (AD). KXS has been widely used to treat emotional diseases; however, its active components remain unknown. There have been some reports about the efficacy and metabolic analysis of KXS, which are mainly based on studying normal animals. The current work first established an AD rat model by injecting D-galactose into the abdominal cavity and injecting Aβ25-35 into the hippocampus on both sides, followed by intragastric administration of KXS for a consecutive week; then, the analytical method for ethanol extraction from the serum of normal and model rats was developed using UPLC-LTQ-Orbitrap-MS; finally, the transitional components in the blood were systematically compared and analyzed by multivariate statistical analysis. A total of 36 components of KXS were identified in the rat serum of the normal group, including 24 prototype components (including ginsenosides, triterpenoid acids of Poria cocos, polygala saponins, polygala xanthones and polygala ester) and 13 metabolites (including desugar, hydration and oxidation products of ginsenosides, triterpenoid acid hydroxylation, deoxygenation, demethylation, desaturation, and glycine-conjugated products of Poria cocos). Twenty KXS-relevant components were detected in the rat serum of the model group, including 11 prototypes and 9 metabolites. The normal group and the model group shared 12 common components, including 9 prototypes and 3 metabolites. The intestinal microecological balance of the model rats probably was destroyed, affecting the absorption/metabolism of saponins by the body, which resulted in fewer transitional components in the model group. This study reflected the drug-body interaction from an objective and accurate perspective, offering references and insights for elucidating the basis of active components and mechanism of action of KXS for treating AD.
Collapse
|
20
|
Zhang S, Li Z, Shu J, Xue H, Guo K, Zhou X. Soil-derived bacteria endow Camellia weevil with more ability to resist plant chemical defense. MICROBIOME 2022; 10:97. [PMID: 35752840 PMCID: PMC9233397 DOI: 10.1186/s40168-022-01290-3] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 02/04/2022] [Accepted: 05/16/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Herbivorous insects acquire their gut microbiota from diverse sources, and these microorganisms play significant roles in insect hosts' tolerance to plant secondary defensive compounds. Camellia weevil (Curculio chinensis) (CW) is an obligate seed parasite of Camellia oleifera plants. Our previous study linked the CW's gut microbiome to the tolerance of the tea saponin (TS) in C. oleifera seeds. However, the source of these gut microbiomes, the key bacteria involved in TS tolerance, and the degradation functions of these bacteria remain unresolved. RESULTS Our study indicated that CW gut microbiome was more affected by the microbiome from soil than that from fruits. The soil-derived Acinetobacter served as the core bacterial genus, and Acinetobacter sp. was putatively regarded responsible for the saponin-degradation in CW guts. Subsequent experiments using fluorescently labeled cultures verified that the isolate Acinetobacter sp. AS23 can migrate into CW larval guts, and ultimately endow its host with the ability to degrade saponin, thereby allowing CW to subsist as a pest within plant fruits resisting to higher concentration of defensive chemical. CONCLUSIONS The systematic studies of the sources of gut microorganisms, the screening of taxa involved in plant secondary metabolite degradation, and the investigation of bacteria responsible for CW toxicity mitigation provide clarified evidence that the intestinal microorganisms can mediate the tolerance of herbivorous insects against plant toxins. Video Abstract.
Collapse
Affiliation(s)
- Shouke Zhang
- State Key Laboratory of Subtropical Silviculture, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China
- College of Forestry and Biotechnology, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China
| | - Zikun Li
- College of Forestry and Biotechnology, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China
| | - Jinping Shu
- Research Institute of Subtropical Forestry, Chinese Academy of Forestry, Zhejiang, Hangzhou, 311400, People's Republic of China.
| | - Huaijun Xue
- College of Life Sciences, Nankai University, Tianjin, 300071, People's Republic of China
| | - Kai Guo
- State Key Laboratory of Subtropical Silviculture, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China
- College of Forestry and Biotechnology, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China
| | - Xudong Zhou
- State Key Laboratory of Subtropical Silviculture, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China.
- College of Forestry and Biotechnology, Zhejiang A&F University, Zhejiang, Hangzhou, 311300, People's Republic of China.
| |
Collapse
|
21
|
Yi H, Yu Z, Wang Q, Sun Y, Peng J, Cai Y, Ma J, Chen Y, Qin C, Cai M, Ji C, Zhang G, Wang H. Panax Notoginseng Saponins Suppress Type 2 Porcine Reproductive and Respiratory Syndrome Virus Replication in vitro and Enhance the Immune Effect of the Live Vaccine JXA1-R in Piglets. Front Vet Sci 2022; 9:886058. [PMID: 35619609 PMCID: PMC9127999 DOI: 10.3389/fvets.2022.886058] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2022] [Accepted: 04/19/2022] [Indexed: 11/13/2022] Open
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) suppresses the innate immune response in the host, reducing and delaying neutralizing antibody production against PRRSV infection and promoting viral infection. Here, we aimed to assess the potential of Panax notoginseng saponins (PNS) for improving the immune response exerted upon PRRSV-2-modified live virus (MLV) vaccine administration. Thirty piglets were randomly divided into six groups. Group 1 piglets were injected with medium 0 days post vaccination (dpv). Group 2 piglets were fed PNS 0–28 dpv. Group 3 and group 4 piglets were administered the JXA1-R vaccine 0 dpv. Group 4 piglets were also fed PNS 0–28 dpv. Group 1–4 piglets were challenged intranasally with the PRRSV JXA1 strain 28 dpv. Group 5 piglets were fed with PNS without challenge. Group 6 piglets served as controls. During the experiment, the samples were collected regularly for 49 days. Compared with group 1 piglets, group 3 piglets showed significantly reduced viremia and clinical scores, and significantly increased average daily gain (ADWG). Compared with group 3 piglets, group 4 piglets showed significantly improved neutralizing antibody titers, IFN-α and IFN-β mRNA expression, and significantly decreased viremia and viral load in the lungs and lymph nodes, but did not demonstrate any further improvement in PRRSV-specific antibody titer, rectal temperature, ADWG, or clinical scores. PNS upregulates neutralizing antibodies against PRRSV-2 and enhances the expression of IFN-α and IFN-β, which may reduce PRRSV viremia upon PRRSV-2 MLV vaccine administration. PNS may serve as an effective immunomodulator for boosting the immune defense against PRRSV.
Collapse
Affiliation(s)
- Heyou Yi
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Zhiqing Yu
- Key Laboratory of Veterinary Bioproduction and Chemical Medicine of the Ministry of Agriculture, Engineering and Technology Research Center for Beijing Veterinary Peptide Vaccine Design and Preparation, Zhongmu Institutes of China Animal Husbandry Industry Co., Ltd., Beijing, China
| | - Qiumei Wang
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Yankuo Sun
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Jie Peng
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Yu Cai
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Jun Ma
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Yongjie Chen
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Chenxiao Qin
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Mengkai Cai
- Guangdong Meizhou Vocational and Technical College, Meizhou, China
| | - Chihai Ji
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
| | - Guihong Zhang
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
- *Correspondence: Guihong Zhang
| | - Heng Wang
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangdong Laboratory for Lingnan Modern Agriculture, Guangdong Provincial Key Laboratory of Prevention and Control for Severe Clinical Animal Diseases, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
- National Engineering Research Center for Breeding Swine Industry, South China Agricultural University, Guangzhou, China
- Heng Wang
| |
Collapse
|
22
|
Fu W, Liang Y, Xie Z, Wu H, Zhang Z, Lv H. Preparation and evaluation of lecithin/zein hybrid nanoparticles for the oral delivery of Panax notoginseng saponins. Eur J Pharm Sci 2021; 164:105882. [PMID: 34000426 DOI: 10.1016/j.ejps.2021.105882] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2021] [Revised: 04/15/2021] [Accepted: 05/11/2021] [Indexed: 10/21/2022]
Abstract
Panax Notoginseng Saponins (PNS) has been widely used in the prevention and treatment of cardiovascular and cerebrovascular diseases such as myocardial infarction, heart failure and cerebral infarction. However, oral administration of PNS showed low bioavailability because of its instability and poor membrane permeability in the gastrointestinal tract. Here, lipoprotein-inspired hybrid nanoparticles of PNS-Lecithin-Zein (PLZ-NPs) were prepared by using a simple phase separation method, which possessed a core-shell structure, where zein was used as protein part to replace the animal origin protein to increase the resistance to acid and enzymes while lecithin was used as the lipid composition to improve the oral absorption of PNS as well as to increase the drug loading capacity of PNS into the nanocarriers. The results of stability test showed that PLZ-NPs had robust enzymolysis resistance ability for acid and digestive enzymes of gastrointestinal environments. The fluorescent resonance energy transfer (FRET) assay confirmed the ability of LZ-NPs to be intactly absorbed by Caco-2 cell monolayer. Cell transport studies demonstrated that the permeability of PLZ-NPs in Caco-2/HT29-MTX co-culture cell model was 1.5-fold that of PNS. Meanwhile, the single-pass intestinal perfusion assay proved the absorption parameter Peff of PLZ-NPs was 1.75 and 1.80 times higher than that of PNS in the ileum and jejunum, respectively. Finally, the in vivo pharmacokinetic experiment showed that the relative oral bioavailability of PLZ-NPs was 1.71-fold that of free PNS in SD rat. In summary, the employment of the Lecithin/Zein hybrid nanoparticles could be considered as a promising approach for PNS analogues.
Collapse
Affiliation(s)
- Wen Fu
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China
| | - Yiping Liang
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China
| | - Zhonghui Xie
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China
| | - Hangyi Wu
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China
| | - Zhenhai Zhang
- Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing 210023, China; Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210028, China.
| | - Huixia Lv
- Department of Pharmaceutics, China Pharmaceutical University, Nanjing 211198, China.
| |
Collapse
|
23
|
Guo YP, Shao L, Wang L, Chen MY, Zhang W, Huang WH. Bioconversion variation of ginsenoside CK mediated by human gut microbiota from healthy volunteers and colorectal cancer patients. Chin Med 2021; 16:28. [PMID: 33731196 PMCID: PMC7968294 DOI: 10.1186/s13020-021-00436-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Accepted: 03/05/2021] [Indexed: 01/04/2023] Open
Abstract
Background Ginsenoside CK (GCK) serves as the potential anti-colorectal cancer (CRC) protopanaxadiol (PPD)-type saponin, which could be mainly bio-converted to yield PPD by gut microbiota. Meanwhile, the anti-CRC effects of GCK could be altered by gut microbiota due to their different diversity in CRC patients. We aimed to investigate the bioconversion variation of GCK mediated by gut microbiota from CRC patients by comparing with healthy subjects. Methods Gut microbiota profiled by 16S rRNA gene sequencing were collected from healthy volunteers and CRC patients. GCK was incubated with gut microbiota in vitro. A LC-MS/MS method was validated to quantify GCK and PPD after incubation at different time points. Results The bioconversion of GCK in healthy subjects group was much faster than CRC group, as well as the yield of PPD. Moreover, significant differences of PPD concentration between healthy subjects group and CRC group could be observed at 12 h, 48 h and 72 h check points. According to 16S rRNA sequencing, the profiles of gut microbiota derived from healthy volunteers and CRC patients significantly varied, in which 12 differentially abundant taxon were found, such as Bifidobacterium, Roseburia, Bacteroides and Collinsella. Spearman’s correlation analysis showed bacteria enriched in healthy subjects group were positively associated with the biotransformation of GCK, while bacteria enriched in CRC group displayed non correlation character. Among them, Roseburia which could secrete β-glycosidase showed the strongest positive association with the bioconversion of GCK. Conclusions The bioconversion of GCK in healthy subjects was much faster than CRC patients mediated by gut microbiota, which might alter the anti-CRC effects of GCK. ![]() Supplementary Information The online version contains supplementary material available at 10.1186/s13020-021-00436-z.
Collapse
Affiliation(s)
- Yin-Ping Guo
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.,Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Xiangya Road 110, 410008, Changsha, China
| | - Li Shao
- Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410128, Hunan, China
| | - Li Wang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.,Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Xiangya Road 110, 410008, Changsha, China
| | - Man-Yun Chen
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.,Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Xiangya Road 110, 410008, Changsha, China
| | - Wei Zhang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China.,Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, China.,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Xiangya Road 110, 410008, Changsha, China
| | - Wei-Hua Huang
- Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, 410008, China. .,Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, 410078, China. .,National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Xiangya Road 110, 410008, Changsha, China. .,NHC Key Laboratory of Birth Defect for Research and Prevention (Hunan Provincial Maternal and Child Health Care Hospital), Changsha, 410008, Hunan, China.
| |
Collapse
|